Mild cognitive impairment is experienced by 30% of Parkinson’s disease patients (PD-MCI), often affecting executive functions. There is currently no pharmacological treatment for PD-MCI. The aim of th
Mild cognitive impairment is experienced by 30% of Parkinson’s disease patients (PD-MCI), often affecting executive functions. There is currently no pharmacological treatment for PD-MCI. The aim of th
